These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 10574417)

  • 1. The effect of pravastatin on renal function and lipid metabolism in patients with renal dysfunction with hypertension and hyperlipidemia. Pravastatin and Renal Function Research Group.
    Imai Y; Suzuki H; Saito T; Tsuji I; Abe K; Saruta T
    Clin Exp Hypertens; 1999 Nov; 21(8):1345-55. PubMed ID: 10574417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of a HMG-CoA reductase inhibitor combined with hormone replacement therapy on lipid metabolism in Japanese women with hypoestrogenic lipidemia: a multicenter double-blind controlled prospective study.
    Ohta H; Komukai S; Sugimoto I; Fuyuki T; Makita K; Takamatsu K; Horiguchi F; Nozawa S
    Maturitas; 1998 Jun; 29(2):163-71. PubMed ID: 9651906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of high dose pravastatin and low dose pravastatin and ezetimibe combination therapy on lipid, glucose metabolism and inflammation.
    Dagli N; Yavuzkir M; Karaca I
    Inflammation; 2007 Dec; 30(6):230-5. PubMed ID: 17687635
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pravastatin therapy in hyperlipidemia: effects on thrombus formation and the systemic hemostatic profile.
    Dangas G; Badimon JJ; Smith DA; Unger AH; Levine D; Shao JH; Meraj P; Fier C; Fallon JT; Ambrose JA
    J Am Coll Cardiol; 1999 Apr; 33(5):1294-304. PubMed ID: 10193730
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyperlipidemia after liver transplantation: natural history and treatment with the hydroxy-methylglutaryl-coenzyme A reductase inhibitor pravastatin.
    Imagawa DK; Dawson S; Holt CD; Kirk PS; Kaldas FM; Shackleton CR; Seu P; Rudich SM; Kinkhabwala MM; Martin P; Goldstein LI; Murray NG; Terasaki PI; Busuttil RW
    Transplantation; 1996 Oct; 62(7):934-42. PubMed ID: 8878387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the lipid-lowering effects of pitavastatin 4 mg versus pravastatin 40 mg in adults with primary hyperlipidemia or mixed (combined) dyslipidemia: a Phase IV, prospective, US, multicenter, randomized, double-blind, superiority trial.
    Sponseller CA; Morgan RE; Kryzhanovski VA; Campbell SE; Davidson MH
    Clin Ther; 2014 Aug; 36(8):1211-22. PubMed ID: 24998014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term safety of pravastatin-gemfibrozil therapy in mixed hyperlipidemia.
    Iliadis EA; Rosenson RS
    Clin Cardiol; 1999 Jan; 22(1):25-8. PubMed ID: 9929751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of pravastatin on proteinuria in patients with well-controlled hypertension.
    Lee TM; Su SF; Tsai CH
    Hypertension; 2002 Jul; 40(1):67-73. PubMed ID: 12105140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The combination of nebivolol plus pravastatin is associated with a more beneficial metabolic profile compared to that of atenolol plus pravastatin in hypertensive patients with dyslipidemia: a pilot study.
    Rizos E; Bairaktari E; Kostoula A; Hasiotis G; Achimastos A; Ganotakis E; Elisaf M; Mikhailidis DP
    J Cardiovasc Pharmacol Ther; 2003 Jun; 8(2):127-34. PubMed ID: 12808486
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacogenetic study of statin therapy and cholesterol reduction.
    Chasman DI; Posada D; Subrahmanyan L; Cook NR; Stanton VP; Ridker PM
    JAMA; 2004 Jun; 291(23):2821-7. PubMed ID: 15199031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness.
    Taylor AJ; Kent SM; Flaherty PJ; Coyle LC; Markwood TT; Vernalis MN
    Circulation; 2002 Oct; 106(16):2055-60. PubMed ID: 12379573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the antiatherosclerotic effects of dihydropyridine calcium channel blocker and HMG-CoA reductase inhibitor on hypercholesterolemic rabbits.
    Takayama M; Matsubara M; Arakawa E; Takada C; Ina Y; Hasegawa K; Yao K
    Vascul Pharmacol; 2007 Apr; 46(4):302-8. PubMed ID: 17197250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined treatment with low-dose pravastatin and fish oil in post-renal transplantation dislipidemia.
    Grekas D; Kassimatis E; Makedou A; Bacharaki D; Bamichas G; Tourkantonis A
    Nephron; 2001 Aug; 88(4):329-33. PubMed ID: 11474227
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation.
    Fliser D; Buchholz K; Haller H;
    Circulation; 2004 Aug; 110(9):1103-7. PubMed ID: 15313950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).
    ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial
    JAMA; 2002 Dec; 288(23):2998-3007. PubMed ID: 12479764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of fluvastatin of hyperlipidemia in renal transplant recipients: a prospective, placebo-controlled study.
    Türk S; Yildiz A; Tükek T; Akkaya V; Aras U; Türkmen A; Uras AR; Sever MS
    Int Urol Nephrol; 2001; 32(4):713-6. PubMed ID: 11989571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical evaluation of the efficacy and safety of manidipine in hypertensive patients with renal disorders.
    Mizuno K; Haga H; Takahashi M; Watanabe Y; Fukuchi S
    Blood Press Suppl; 1992; 3():119-23. PubMed ID: 1343279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term safety and efficacy of combination gemfibrozil and HMG-CoA reductase inhibitors for the treatment of mixed lipid disorders.
    Murdock DK; Murdock AK; Murdock RW; Olson KJ; Frane AM; Kersten ME; Joyce DM; Gantner SE
    Am Heart J; 1999 Jul; 138(1 Pt 1):151-5. PubMed ID: 10385779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of manidipine in the treatment of hypertension with renal impairment: a multicenter trial.
    Saruta T; Suzuki H
    Am Heart J; 1993 Feb; 125(2 Pt 2):630-4. PubMed ID: 8430609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of coronary spastic angina with a statin in addition to a calcium channel blocker: a pilot study.
    Tani S; Nagao K; Anazawa T; Kawamata H; Furuya S; Takahashi H; Iida K; Fuji T; Matsumoto M; Kumabe T; Sato Y; Hirayama A
    J Cardiovasc Pharmacol; 2008 Jul; 52(1):28-34. PubMed ID: 18594477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.